An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Insulin RinGlar ("Geropharm", Russia) Compared to Lantus SoloStar ("Sanofi-Aventis Deutschland GmbH", Germany) in Type 1 Diabetes Mellitus Patients
Latest Information Update: 22 Jul 2019
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors GEROPHARM
Most Recent Events
- 22 Jul 2019 New trial record